RLMD (Relmada Therapeutics) Stock Based Compensation: $15.02 Mil (TTM As of Mar. 2026)


RLMD Relmada Therapeutics Inc RLMD
29 GF Score
Price $6.41
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics Stock Based Compensation?

Relmada Therapeutics RLMD -1.46% 29 Stock Based Compensation is $15.02 Mil as of Mar. 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Relmada Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $3.63 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $15.02 Mil.

Relmada Therapeutics Stock Based Compensation Related Terms

Relmada Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Relmada Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics Stock Based Compensation Chart

Relmada Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.49 44.20 43.81 30.19 14.96

Relmada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.58 4.38 3.80 3.21 3.63
RLMD
29GF Score
Relmada Therapeutics Inc RLMD
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.02 Mil.

What does a Stock Based Compensation of $15.02 Mil mean?
Relmada Therapeutics (RLMD) has a Stock Based Compensation of $15.02 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Relmada Therapeutics and its competitors.
Is Relmada Therapeutics' Stock Based Compensation too high?
Relmada Therapeutics' current Stock Based Compensation is $15.02 Mil. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' Stock Based Compensation compare to ACRS and GYRE?
Relmada Therapeutics' Stock Based Compensation of $15.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Relmada Therapeutics and its competitors. Relmada Therapeutics's current Stock Based Compensation is $15.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current Stock Based Compensation of $15.02 Mil. The current Stock Based Compensation is $15.02 Mil. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current Stock Based Compensation is $15.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Other Exchanges 4E2:Germany
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score

Get the complete analysis for RLMD

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.41
Price